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The antigen-binding fragment of the broadly neutralizing human immunodeficiency virus type 1 (HIV-1)
antibody 2G12 has an unusual three-dimensional (3D) domain-swapped structure with two aligned combining
sites that facilitates recognition of its carbohydrate epitope on gp120. When expressed as an intact immuno-
globulin G (IgG), 2G12 formed typical IgG monomers containing two combining sites and a small fraction of
a higher-molecular-weight species, which showed a significant increase in neutralization potency (50- to 80-fold
compared to 2G12 monomer) across a range of clade A and B strains of HIV-1. Here we show that the
higher-molecular-weight species corresponds to a 2G12 dimer containing four combining sites and present a
model for how intermolecular 3D domain swapping could create a 2G12 dimer. Based on the structural model
for a 3D domain-swapped 2G12 dimer, we designed and tested a series of 2G12 mutants predicted to increase
the ratio of 2G12 dimer to monomer. We report a mutation that effectively increases the 2G12 dimer/monomer
ratio without decreasing the expression yield. Increasing the proportion of 2G12 dimer compared to monomer
could lead to a more potent reagent for gene therapy or passive immunization.
Broadly neutralizing antibodies against human immunode-
ficiency virus type 1 (HIV-1) have attracted attention not only
for the lessons they provide for designing vaccine antigens to
induce a more robust immunological response (2) but also as
potential therapeutic reagents. Although HIV infection leads
to a vigorous antibody response, most antibodies fail to control
the virus due to targeting of non-neutralizing epitopes or the
ability of escape mutants to quickly develop against neutraliz-
ing antibodies (23). Correlating with the ability of the virus to
elude antibodies, the majority of neutralizing antibodies are
highly strain specific. Nevertheless, a small set of broadly neu-
tralizing antibodies has been isolated from the blood of HIV-
infected individuals, and these reagents have been extensively
studied (2). Clinical trials using a cocktail of three such anti-
bodies—2G12, 4E10, and 2F5—have demonstrated a partial
ability to suppress viral replication (13, 20, 21).
The 2G12 antibody has an unusual structure that facilitates
recognition of its carbohydrate epitope on gp120 (4). Whereas
typical immunoglobulin G (IgG) antibodies contain two flexi-
bly attached antigen-binding fragments (Fabs), resulting in two
antigen-binding sites separated by distances ranging from 120
to 150 Å in structures of intact IgGs (6, 7, 17), the Fab arms of
2G12 are entwined in such a way as to create a single antigen-
binding region with two rigidly arranged antigen-binding sites
separated by 35 Å (4) (Fig. 1A and B). The entwined struc-
ture of the 2G12 Fabs results from three-dimensional (3D)
domain swapping (1) in which each 2G12 light chain associates
with both heavy chains: the light-chain variable domain (VL) is
paired with the variable domain of one heavy chain (VH), while
the light constant domain (CL) is paired with constant domain
1 (CH1) of the partner heavy chain (Fig. 1B). This domain-
swapped arrangement prevents the Fab arms from having the
normal flexibility observed in other antibodies but, by possess-
ing a double-sized antigen-combining site, the 2G12 Fab2 unit
is able to recognize clusters of mannose-rich carbohydrates
that occur on gp120 (18). Normally, these carbohydrates create
a glycan shield on the HIV envelope glycoprotein (Env) spike
that helps the virus evade the host antibody response (23).
During expression of 2G12 in mammalian cells, we observed
the production of IgG monomers (i.e., two heavy chains, two
light chains, and thus two Fabs), as typically formed by other
IgGs, and a higher-molecular-weight fraction that exhibited a
significantly increased neutralization potency. Here, we show
that the higher-molecular-weight fraction corresponded to a
2G12 dimer with four heavy chains, four light chains, and four
Fabs and present a model for how 3D domain swapping could
create a 2G12 dimer. We used the model of the 2G12 dimer to
design mutations predicted to increase the fraction of dimer
being expressed and report a mutation that effectively in-
creases the 2G12 dimer/monomer ratio without decreasing the
expression yield.
MATERIALS AND METHODS
Materials. Sequences encoding the 2G12 VH-CH1 and VL-CL domains in the
pComb3H expression vector (a gift from Dennis Burton, The Scripps Research
Institute) were subcloned into the bicistronic baculovirus vector pAc--Fc
(PROGEN Biotechnik), which contains the gene for the Fc region of human
IgG1 (G1m marker). The heavy-chain gene, now including the hinge and Fc
regions (residues 236 to 446, numbered according to the method of Kabat et al.
[11]), and light-chain gene were each subcloned into the mammalian expression
vector pTT5 (NRC Biotechnology Research Institute) for expression in
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HEK293-6E cells. Mutations were introduced in the 2G12 heavy-chain gene by
using a QuikChange mutagenesis kit (Stratagene). Seven different forms of the
2G12 heavy-chain gene were constructed: our original 2G12 sequence, which
differed from previously reported 2G12 and IgG1 Fc sequences (4) by two
substitutions (V5L and H237S), and six hinge deletion mutants constructed from
our original 2G12 sequence. The mutants were D1 (deletion of residue 237), D2
(deletion of residues 236 to 237), D3 (deletion of residues 235 to 237), D4
(deletion of residues 232 to 237), D6 (deletion of residues 232 to 239), and
D6GG (deletion of residues 232 to 239 and two proline-to-glycine substitutions
[P240G and P241G]) (see Fig. 3A). In addition, we produced forms of the
original 2G12 sequence and of the D2 mutant that reverted the V5L and H237S
substitutions to the previously reported 2G12 and IgG1 Fc sequences.
Expression of 2G12. Proteins were expressed by using polyethylenimine-me-
diated transient transfection (5) of suspension HEK293-6E cells (NRC Biotech-
nology Research Institute). The 2G12 heavy- and light-chain expression vectors
were cotransfected at a 1:1 ratio using 25-kDa linear polyethylenimine (Poly-
sciences). Cell culture supernatants were collected at 6 days posttransfection,
passed over protein A resin (Pierce Biotechnology), and eluted using a pH 3.0
citrate buffer. Eluates from the protein A column were immediately neutralized
and then subjected to size exclusion chromatography in 20 mM Tris (pH 8.0)–150
mM NaCl using a Superdex 200 16/60 or 10/30 column (GE Healthcare). The
column profile revealed two major peaks, later identified as 2G12 dimer and
2G12 monomer. Similar results were obtained when the original 2G12 construct
and the D2 mutant were purified from cell culture supernatants by passage over
a neonatal Fc receptor affinity column in which supernatants were passed over
the column at pH 6.0 and eluted at pH 8.0 (8).
Since the sizing column profiles of the monomeric and dimeric forms of 2G12
partially overlapped, samples for neutralization assays were subjected to two size
exclusion chromatography purification steps: first, the concentrated protein A
eluate was run over a Superdex 200 16/60 column, and then the monomer and
dimer fractions were placed over a Superdex 200 10/30 column.
Parallel trials of the original 2G12 construct and six hinge deletion mutants
were performed on a 400-ml scale. Five independent expression trials, each
involving all seven constructs, were conducted. In each trial, 2G12 proteins were
purified on a protein A column as described above and then subjected to size
exclusion chromatography. Dimer-to-monomer ratios for each construct (see
Fig. 3C) were calculated after integration of the peak areas using UNICORN
software. In four of the five trials, the expression of total 2G12 protein in each
sample was approximately 2 mg/liter. In the fifth trial, the total expression in each
sample was10-fold lower, likely due to suboptimal transfections. The data from
this trial were omitted from the calculated means shown in Fig. 3C.
Static light scattering. The oligomeric states of the two 2G12 peaks isolated by
conventional size exclusion chromatography were determined using size exclu-
sion chromatography with in-line static light scattering and refractive index
monitoring. Experiments were performed at 25°C using an A¨KTA chromatog-
raphy system (GE Healthcare) with a Superdex 200 10/30 (GE Healthcare)
equipped with a Dawn Helios multi-angle light scattering photometer and an
Optilab rEX refractive index detector (Wyatt Technology). Bovine serum albu-
min was used as a calibration standard. All data were analyzed with ASTRA V
software (Wyatt Technology).
In vitro neutralization assays. We used a previously described pseudovirus
neutralization assay, which measures the reduction in luciferase reporter gene
expression in the presence of a potential inhibitor following a single round of
pseudovirus infection in TZM-bl cells (12, 14). Pseudoviruses were generated by
cotransfection of HEK293T cells with an Env expression plasmid and a replica-
tion-defective backbone plasmid. Neutralization assays were performed either
in-house (data shown only for strain HxBc2) or by the Collaboration for AIDS
Vaccine Discovery (CAVD) core neutralization facility (Table 1). Strains
SC422661.8, TRO.11, PVO.4, QH0692.42, 6535.3, and HxBc2 were tested in-
house, with results similar to those obtained from the CAVD assays. For in-
house assays, each 2G12 sample was tested in triplicate, with 200 infectious viral
units per well incubated with a threefold dilution series. After a 1-h incubation
at 37°C, 10,000 TZM-bl cells were added to each well, followed by incubation for
2 days. Cells were then lysed and assayed for luciferase expression by using
Bright-Glo (Promega) and a Victor3 luminometer (Perkin-Elmer). The percent
neutralization was determined by calculating the difference in luminescence
between test wells and cell control wells (cell only), dividing this value by the
difference between virus control (cell plus virus) and cell control wells, subtract-
ing from 1, and multiplying by 100. Nonlinear regression analysis was used to
calculate concentrations at which half-maximal inhibition was observed (IC50s).
The average IC50s reported in Table 1 are geometric means calculated by using
the formula (ai)(1/n), where i  1, 2, . . ., n. Calculation of geometric means is
suitable for data sets covering multiple orders of magnitude (19), as is the case
for neutralization data across multiple viral strains.
Biacore binding studies. A Biacore T100 biosensor system (GE Healthcare)
was used to evaluate binding of the 2G12 proteins to gp120. In this system, a
protein is coupled to a gold-dextran layer, and association and dissociation
phases for binding to an injected protein are measured in real time in resonance
units (RU). The original 2G12 monomer and dimer and the D2 dimer (150 RU
of each) were captured onto 4,000 RU of goat anti-Fc polyclonal antibody
(Chromapure; Jackson ImmunoResearch), which was immobilized by primary
amine coupling to a CM5 sensor chip as described in the Biacore manual. A
concentration series of monomeric gp120 (expressed in baculovirus-infected
insect cells; strain HxBc2) was injected at 20 l/min over the flow cells. After the
gp120 dissociation phase, the surface was regenerated by injection of pH 1.5
glycine buffer, and 2G12 proteins were captured again prior to the subsequent
gp120 injection.
Structural analysis. The 2G12 structure was displayed and analyzed by using
the program O (10). The 3D model of 2G12 was prepared using SolidWorks
(SolidWorks Corp.).
RESULTS
Identification of a dimeric form of 2G12 with increased
neutralization potency. During purification of 2G12 IgG ex-
pressed in mammalian cells, we noticed that the protein eluted
FIG. 1. Schematic structures of a typical IgG and 2G12. Heavy
chains are blue in panels A and B and blue or red in panel C, light
chains are cyan, disulfide bonds are yellow lines, and the antigen
combining sites are yellow starbursts. (A) Schematic diagram showing
the domain arrangement of a typical IgG, which contains two identical
heavy chains and two identical light chains. (B) Schematic diagram
(left) and a corresponding 3D model (right) illustrating chain pairing
in monomeric 2G12 (based on structural data from reference 4). As a
result of intramolecular 3D domain swapping, each heavy chain forms
part of both Fab units to create a rigidly arranged Fab2 unit. To
distinguish the two heavy chains, they are labeled 1 or 2 in the sche-
matic diagram. (C) Schematic diagram (left) and corresponding 3D
model (right) illustrating chain pairing in dimeric 2G12. The proposed
dimer structure resulting from intermolecular 3D domains swapping
has the same domain-swapped Fab2 unit as the monomer, but the
connectivity to the Fc domains is altered. To distinguish the four heavy
chains, they are labeled 1, 2, 3, or 4 in the schematic diagram and are
red in one of the IgG monomer precursors.
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as two peaks from a size exclusion chromatography column
(peak 1, eluting at12 ml, and peak 2, eluting at10 ml) (Fig.
2A). Peak 1 migrated as if it were a somewhat larger protein
than a typical IgG, which eluted at 13 ml, suggesting that it
corresponded to a 2G12 monomer, which has a more elon-
gated structure than other IgG monomers due to the 3D do-
main-swapped structure of its Fabs (4) (Fig. 1B). Peak 2 ap-
peared to correspond to a higher-molecular-weight form of
2G12. Samples from both peaks migrated on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis under nonreducing
conditions, as expected for an IgG (Fig. 2B), indicating that
covalent modification(s) could not account for the altered mi-
gration of peak 2. Once isolated, both peaks retained their size
exclusion profile over a period of weeks to months, indicating
that there was little tendency for conversion between the two
forms.
In-line static multi-angle light scattering was used to deter-
mine the absolute molecular masses, and therefore the oligo-
meric states, of both peaks. For this analysis, we used the major
portion of peak 2 and did not include the shoulder slightly
ahead of the peak. The experimentally determined molecular
masses derived from these data were 135 kDa for peak 1 and
285 kDa for peak 2. By comparing these values with the mo-
lecular mass predicted from the 2G12 sequence (145 kDa), we
identified peak 1 as 2G12 monomer and peak 2 as 2G12 dimer.
We next compared the potencies of purified 2G12 monomer
and dimer to neutralize a range of HIV-1 pseudoviruses by
using an in vitro neutralization assay (12, 14). The 2G12 mono-
mer neutralized a range of clade A and B, but not clade C,
strains (Table 1). Over the range of strains that were sensitive
to 2G12 neutralization, the 2G12 dimer was generally 1 to 2
orders of magnitude more potent than the 2G12 monomer,
with an average increased potency of 82-fold (Table 1). Three
of the twenty strains that were not neutralized by monomeric
2G12 (IC50  100 g/ml) were neutralized by dimeric 2G12:
strains TRJO4551.58 (clade B) and strains 211-9 and T280-5
(circulating recombinant forms) (Table 1). The clade C strains
remained resistant to 2G12 dimer (Table 1 legend).
Design and expression of 2G12 mutants. Given that the
2G12 dimer was not formed by covalent joining of two mono-
mers (Fig. 2B), we reasoned that the dimeric form could arise
from intermolecular 3D domain swapping in which each light
chain was paired with heavy chains derived from two IgGs (Fig.
1C). In contrast, the intramolecular domain swapping observed
in monomeric 2G12 involves the pairing of each light chain
with both heavy chains from a single IgG (4) (Fig. 1B).
To increase the dimeric fraction of 2G12, we designed mu-
tants predicted to favor intermolecular domain swapping in-
stead of the intramolecular swapping that led to the monomer.
Compared to a typical antibody, the hinge regions of the do-
main-swapped 2G12 are forced into a relatively extended con-
formation. In other words, the C-terminal ends of the 2G12
CH1 domains (defined by residue K228) are held fixed at a
large distance: the K228-K228 distance is 40.6 Å in the 2G12
Fab2 structure (pdb code 1OP3) (4) versus 25.0 Å for the
corresponding distance in an unswapped antibody structure
TABLE 1. IC50s for four forms of 2G12 obtained from in vitro pseudovirus neutralization assays of 2G12-sensitive strains
a
Env clone Clade
2G12 original D2
Monomer IC50
(g/ml)
Dimer IC50
(g/ml)
Monomer IC50/
dimer IC50
Monomer IC50
(g/ml)
Dimer IC50
(g/ml)
Monomer IC50/
dimer IC50
6535.3 B 30.1 0.34 89 32.9 1.5 22
QH0692.42 B 9.8 0.08 123 11.1 0.1 111
SC422661.8 B 17.8 0.05 356 19.4 0.1 194
PVO.4 B 4.9 0.05 98 7.1 0.05 142
TRO.11 B 1.6 0.05 32 1.4 0.05 28
WITO4160.33 B 6.8 0.05 136 7.6 0.05 152
3988.25 B 3.2 0.05 64 2.8 0.05 56
7165.18 B 6.6 0.05 132 8 0.05 160
QH0515.1 B 0.1 0.05 2 0.1 0.05 2
5768.4 B 0.1 0.05 2 0.1 0.05 2
6101.1 B 24 0.05 480 26.5 0.06 442
TRJO4551.58 B 100 0.16 625 NDb ND ND
HxBc2* B 0.47 0.028 17 ND ND ND
0330.v4.c3 A 15.3 0.05 306 17.2 0.05 344
3415.v1.c1 A 8 0.05 160 8.1 0.05 162
CHO38.12 CRF07_BC 0.2 0.05 4 0.3 0.05 6
211-9 CRF02_AG 100 0.4 250 100 1.3 77
235-47 CRF02_AG 1.3 0.05 26 1.4 0.05 28
T280-5 CRF02_AG 100 1 100 51 4.9 10
T250-4 CRF02_AG 61.5 0.05 1230 60.7 0.4 152
T251 CRF02_AG 50.8 0.1 508 46.6 0.3 155
Avg (geometric
mean)
6.3 0.08 82 6.5 0.12 54
a Results from in-house neutralization assays are indicated by an asterisk; all other results were obtained by the CAVD core neutralization facility. In calculating
average IC50s, measurements outside of the range of the assay (0.05 or 100 g/ml) were assigned to those limiting values, and averages were calculated using only
strains for which IC50s were available for all four forms of 2G12. The following clade B and C strains were not neutralized by the original 2G12 monomer or dimer
(IC50 values  100 g/ml): AC10.0.29, RHPA4259.7, THRO4156.18, REJO4541.67, and CAAN5342.A2 (clade B) and Du156.12, Du172.17, Du422.1, ZM197M.PB7,
ZM214M.PL15, ZM233M.PB6, ZM249M.PL1, ZM53M.PB12, ZM109F.PB4, ZM135M.PL10a, CAP45.2.00.G3, and CAP210.2.00.E8 (clade C).
b ND, not determined.
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(b12 IgG; pdb code 1HZH) (17). Intramolecular domain swap-
ping, as occurs in monomeric 2G12, may be disfavored by a
shorter hinge region, which could instead accommodate an
intermolecular domain swap resulting in an intertwined IgG
dimer instead of an intertwined IgG monomer (Fig. 1B and C).
Based on this structural hypothesis we designed forms of 2G12
with shorter hinge regions.
A series of deletions was made in the 2G12 heavy chain
between residue C230, which normally participates in a disul-
fide bond with the light chain, and residues C239 and C242,
which form disulfide bonds between the heavy chains (Fig.
3A). The mutants were named according to how many residues
were deleted, with D1 referring to a single residue deletion, up
to D6, which represented a six-residue deletion. An additional
mutant, D6GG, in which two prolines were replaced with gly-
cines to allow increased flexibility, was also prepared.
The original 2G12 construct was expressed, along with the
suite of mutants in multiple expression trials. During each trial,
the expressed IgGs were purified from transfected cell super-
natants on a protein A column, followed by size exclusion
chromatography to separate 2G12 monomer and dimer. The
amounts of dimer and monomer produced by each construct
were determined by integrating the area under the relevant
size exclusion chromatography peak (Fig. 3B). As shown in
Fig. 3C, the D2 mutant had a significantly higher dimer/mono-
mer ratio (0.66 	 0.06) than the original 2G12 (0.28 	 0.03).
The other mutants showed only slightly higher dimer/monomer
ratios (D3 to D6, D6GG) or a lower ratio (D1) than the
original 2G12. A comparison of the total expression levels
(monomer plus dimer) of the original and D2 constructs
showed that the D2 mutation did not impair overall expression
(Fig. 3C).
2G12 protein has been reported to aggregate under strongly
acidic conditions (16). To address whether the low pH used
during elution from the protein A column affected the ability
of 2G12 to dimerize, we purified 2G12 from transfected cell
supernatants by using a neonatal Fc receptor affinity column in
which samples were loaded at pH 6.0 and eluted at pH 8.0 (8).
Size exclusion chromatography profiles of the original 2G12
and the D2 mutant were similar for both purification schemes,
indicating that dimer formation was not affected by the protein
A elution conditions. In addition, we verified that our results
were not influenced by two substitutions in our 2G12 construct
compared to the published sequences of 2G12 Fab2 and hu-
man IgG1 Fc that were introduced during cloning (see Mate-
rials and Methods). To ascertain the effects of the substitu-
tions, we produced versions of the original 2G12 construct and
the D2 mutant in which the substitutions were reverted and
found no significant differences in the total yields of 2G12
protein and the dimer/monomer ratios for the reverted con-
structs compared to the constructs containing the two substi-
tutions: the average total yields for both reverted constructs
were within 8% of the unreverted constructs, and the dimer/
monomer ratios for the reverted 2G12 and the D2 mutant
constructs were 0.34 	 0.03 (reverted 2G12) and 0.76 	 0.06
(reverted D2 mutant).
To verify that the substitutions in the D2 mutant did not
affect its neutralization activity, we determined the neutraliza-
FIG. 2. Size exclusion chromatography profile of 2G12. (A) Comparison of the elution profiles of protein A-purified 2G12 with a typical human
IgG. The more elongated structure of the 2G12 IgG monomer (peak 1) caused it to elute slightly earlier than typical IgGs. (B) Sodium dodecyl
sulfate–7.5% polyacrylamide gel electrophoresis of a typical human IgG and the 2G12 proteins in peaks 1 and 2. Samples were run under
nonreducing conditions. (C) Multi-angle light scattering data obtained by size exclusion chromatography with in-line light scattering and refractive
index monitoring. UV absorbance at 280 nm is shown in black, and the calculated molecular weight based on multi-angle light scattering data is
indicated in blue with units shown on the right axis. The windows used for calculating the molecular masses of peak 1 and peak 2 are shown in gray.
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tion potencies of monomeric and dimeric D2 for the strains
that were tested for the original 2G12 monomer and dimer. As
seen for the original 2G12 dimer, the D2 dimer was more
potent in neutralization of 2G12-sensitive strains than the cor-
responding monomer, and two of the strains that were resistant
to the original 2G12 monomers were sensitive to D2 2G12
dimers (Table 1). The average IC50 for the D2 dimer (0.12
g/ml) was slightly higher than the average value for the orig-
inal dimer (0.08 g/ml), and the overall monomer IC50/dimer
IC50 ratio for the D2 mutant (54-fold) was lower than the
corresponding ratio for the original 2G12 dimer (82-fold).
However, the differences in neutralization potencies of the D2
and original 2G12 dimers are not necessarily significant be-
cause the dimer IC50 averages that were used to derive the
ratios were calculated using strains with IC50s that were below
the sensitivity limit (0.05 g/ml) of our assay; these are re-
ported as0.05 g/ml in Table 1 and input as 0.05 g/ml in the
calculations of averages.
To address whether dimeric 2G12 exhibits higher neutral-
ization potencies than monomeric 2G12 because of avidity
effects (i.e., higher apparent affinity resulting from multivalent
binding), we compared the binding of gp120 to the two forms
of 2G12. In these experiments, the original 2G12 monomer
and dimer and the D2 dimer were coupled to a biosensor chip,
and the binding of injected monomeric HxBc2 gp120 was eval-
uated. No significant differences were observed for the inter-
actions with gp120 of the dimers compared to the monomer:
the equilibrium dissociation constants (KDs) were 1 nM for
the binding of gp120 to the original monomer, the original
dimer, and the D2 dimer (data not shown). These results do
not rule out avidity effects as a mechanism for increased neu-
tralization potency, however, since the gp120 monomers would
not contain the same arrangement of carbohydrate epitopes as
a trimeric gp120/gp41 envelope spike on the surface of a virus.
DISCUSSION
Unlike other known broadly neutralizing anti-HIV-1 anti-
bodies, 2G12 recognizes a carbohydrate, rather than protein,
epitope on gp120 (18, 22). The unusual domain-swapped struc-
ture of its Fab2 unit facilitates recognition of adjacent oligo-
mannose units on the same envelope spike (3). Multimeriza-
tion of 2G12 has been reported to increase the neutralization
potency of 2G12; an engineered IgM form of 2G12, which
contained 10 Fabs (as compared to 2 in a monomeric IgG), was
shown to neutralize up to 28-fold better than monomeric 2G12
IgG (24). Previous investigators suggested that 2G12 IgG
might form dimers with higher neutralization potency; for ex-
ample, the severalfold higher neutralization potency for 2G12
produced in transgenic maize as opposed to mammalian cells
was ascribed to a higher dimer or aggregate content (15), and
2G12 IgG dimers are mentioned but not characterized or di-
rectly compared to 2G12 IgM or 2G12 monomers by Wolbank
et al. (24). Here we report a higher-molecular-weight form of
2G12 IgG that is naturally produced during expression in
FIG. 3. 2G12 deletion constructs. (A) Amino acid sequences of the hinge region of the original 2G12 and the six deletion mutants (left) and
approximate location of the hinge deletions on a schematic structure of a normal IgG (right). (B) Size exclusion chromatography profiles of the
original 2G12 and the deletion mutants. Absorbance traces are shown for one expression trial, normalized on the monomer peak height.
(C) Dimer/monomer ratios for the original 2G12 and the deletion mutants. The data are presented as the means and standard deviations for ratios
determined from four independent expression trials, each of which involved the expression of all seven constructs. Also shown is the mean total
expression relative to the original 2G12 construct. The P value comparing the original 2G12 and the D2 mutant was computed by using the
two-sided independent sample Student t test.
102 WEST ET AL. J. VIROL.
 o
n
 April 13, 2016 by CALIFO
RNIA INST O
F TECHNO
LO
G
Y
http://jvi.asm.org/
D
ow
nloaded from
 
mammalian cells, and we present biophysical evidence that it
represents a dimeric IgG.
We compared the potencies of isolated 2G12 dimer and
monomer for neutralization of a range of clade A and clade
B HIV-1 strains, and report that the 2G12 dimer has a
50-fold average increased potency compared to the mono-
mer. The high neutralization potency of 2G12 dimers sug-
gests that the dimeric fraction of 2G12 would be a better
candidate for passive immunotherapy to treat HIV-1 infec-
tion than the monomeric fraction, which appears to have
been used in previous studies of the efficacy of passive im-
munization using anti-HIV antibodies (13, 21). Another
form of 2G12 that could be considered for passive immuni-
zations is an engineered IgM form, which was reported to
exhibit up to an 28-fold increase in neutralization potency
compared to 2G12 IgG (24). Because the previous study
used a different neutralization assay and different viral
strains, the average neutralization potency increases cannot
be directly compared, but their similarity in magnitude sug-
gests that the extra Fab2 units in the pentameric IgM form
compared to the dimeric form do not contribute significantly
to more effective neutralization. In any case, the choice of
an optimal therapeutic reagent depends on other factors in
addition to neutralization potency, including in vivo half-
life, tissue distribution, antibody-dependent cellular cyto-
toxicity activity, and expression yield. Given the longer se-
rum half-lives of IgG versus IgM antibodies (9), the activity
of IgG antibodies in antibody-dependent cellular cytotoxic-
ity (9) and the more complex assembly and heterogeneity of
recombinant J chain-containing IgM and IgA, the dimeric
IgG form of 2G12 is likely to have several advantages com-
pared to the IgM form.
Based on the propensity of 2G12 monomers to form an
intramolecular domain-swapped Fab2 structure, we present a
structural model for the organization of the 2G12 dimer that
involves intermolecular 3D domain swapping (Fig. 1C). We
used the structural model to design and express 2G12 mutants
predicted to have a higher fraction of the more potent dimeric
form. One of these mutants, D2, had a significantly higher
dimer content and equivalent overall expression. Due to the
much higher neutralization potencies of the original and the
D2 mutant dimers, a modest fraction of dimer can dominate
the overall potency of a 2G12 preparation with a mixture of
forms. Different 2G12 dimer fractions may occur in different
expression contexts, perhaps relating to the density of assem-
bling 2G12 in the endoplasmic reticulum, which could influ-
ence the rates of intra- versus intermolecular domain swap-
ping. Further experiments will be required to investigate the
extent to which the D2 mutant increases dimer fraction in
other expression systems. Although the mechanism by which
the D2 mutant causes a higher dimer content is not known for
certain, this mutant would be a potentially useful therapeutic
reagent in any context in which unfractionated 2G12 is utilized.
This includes gene therapy applications, topical (microbicide)
use, and use as an injectable reagent.
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